All In Biotech

NDA 208399 · Tersera

Varubi

Rolapitant Hydrochloride · Intravenous

Discontinued

Last checked: Nov 20, 2026Latest source record: Aug 19, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Oct 25, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

13

3 Phase 3, 0 recruiting

FAERS reports

539

418 serious, 164 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • VARUBI · ROLAPITANT HYDROCHLORIDE EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML) · EMULSION, INTRAVENOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Rolapitant" as an intervention, any sponsor and status, largest first.

All 13 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death143
  • nausea79
  • fatigue51
  • infusion related reaction40
  • dyspnoea34
  • decreased appetite33
  • flushing32
  • diarrhoea30
  • thrombocytopenia29
  • dehydration22
  • vomiting22
  • chest discomfort21

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201317
20141
20151
201694
2017111
201896
201960
2020116
202118
20224
20234
20247
20253
20267

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Varubi (Rolapitant HCl)

2024 spending

$533K

Beneficiaries

167

527 claims

Per beneficiary

$3,191

$321.85 per unit

View as table
YearSpending
2020$738,837
2021$901,960
2022$820,442
2023$497,575
2024$532,977

Part B: Varubi (Rolapitant HCL) · HCPCS J8670

2024 spending

$9K

Beneficiaries

18

32 claims

Per beneficiary

$498

2024 ASP limit $1.64 per unit

View as table
YearSpending
2020$0
2021$0
2022$7,128
2023$0
2024$8,967

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 28 on PubMed

Sponsor: Tersera

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.